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Abstract 
Purpose
To evaluate the safety and efficacy of trabeculectomy with or without mitomycin-C (MMC) 
in the management of glaucoma in aphakia and pseudophakia following congenital cataract 
surgery. 
  
Patients and methods
All patients of glaucoma with aphakia or pseudophakia who underwent trabeculectomy with 
or without MMC from January 1989 to April 2000 were included. The medical records of 19 
consecutive patients (23 eyes) were reviewed. Data collected from a retrospective chart 
review were analysed. Outcome measures were evaluated using Kaplan–Meier survival 
analysis. Pre- and postoperative intraocular pressures (IOPs), visual acuities, success rate, 
bleb characteristics, surgical failure and complications were the main outcome measures. 
Successful IOP control was defined as an IOP between 6 and 21 mmHg, without 
antiglaucoma medications, without further antiglaucoma surgery and without any sight-
threatening complication. 
  
The mean age of patients was 8.8 5.5 years at the time of trabeculectomy with MMC 
compared to 11.0 12.4 years for trabeculectomy without MMC. Eight patients underwent 
trabeculectomy with MMC and 11 patients underwent trabeculectomy without MMC. There 
was no statistically significant difference between the two groups in terms of visual acuity, 
IOP, antiglaucoma medications, age at cataract surgery and at trabeculectomy. The IOP 
reduced from a preoperative level of 34.2 8.9 mmHg (range: 20–52) to a postoperative level 
of 18.4 12.2 mmHg (range: 2–60) with a mean follow-up of 24.2 17.9 months. The mean 
reduction in IOP in the MMC group was 15.5 17.3 and 16.3 13.8 mmHg in the other group 
(P=0.967). Overall, complete success was achieved in 36.8%, qualified success in 21.1% and 
Results 
surgical failure in 42.1% of patients with a mean follow-up of 24.2 17.9 months. There was 
no difference in the success between the two groups at the last follow-up. One patient 
developed bleb-related endophthalmitis in both eyes following trabeculectomy with MMC. 
Conclusions
The success rate of trabeculectomy in glaucoma following congenital cataract surgery was 
36.8% at the end of 3 years. The present study proves a poor success rate of trabeculectomy 
in a small series of aphakic Asian Indian patients even with the use of MMC. 
  
Introduction 
Glaucoma in aphakia and pseudophakia is one of the most common complications of 
congenital cataract surgery.1 The incidence of such glaucoma as reported in the early 
literature ranges from 0.9 to 14%.2 The incidence in more recent literature ranges from 6 to 
24%, depending on the series.3,4,5,6,7,8 While medical treatment should be tried first to lower 
the intraocular pressure (IOP), surgical procedure is often required to adequately control it.1,3 
Standard glaucoma filtering surgery (trabeculectomy) has its own limitations with a poor 
success rate in the younger age group.9,10,11 The barriers to success of filtering surgery in 
children and younger individuals include a thick and active Tenon's capsule and rapid wound 
healing response.12 Recently, intraoperative mitomycin-C (MMC) has been shown to be an 
effective adjunct chemotherapy with trabeculectomy including glaucoma following 
congenital cataract surgery.13,14,15,16,17,18,19,20,21,22 However, with the exception of the study by 
Walton,22 other reports have presented results of different procedures in all childhood 
glaucomas grouped together.17,18,19,20,21 Azuara-Blanco et al18 had limited success in aphakic 
childhood glaucoma. In their study, the probability of having IOP <21 mmHg with no 
antiglaucoma medication and with clinically stable glaucoma 1 year after trabeculectomy 
with MMC was 0% in the aphakic eyes (n=8).18 They commented that an alternative 
therapeutic approach to aphakic childhood glaucoma might be needed. In contrast, aphakic 
glaucoma patients did well after congenital cataract surgery with MMC trabeculectomy with 
success rates ranging from 62 to 82%, depending on the other reported series.17,19,20,21,22 
However, most of the series included only few patients with short or unknown follow-up. 
The purpose of the present study is to provide additional information regarding the outcome 
of trabeculectomy with or without MMC in a homogenous series of patients with glaucoma in 
aphakia or pseudophakia following congenital cataract surgery and to identify the risk factors 
for failure of this procedure. 
Patients and methods 
A retrospective review of medical records identified all patients of glaucoma in aphakia and 
pseudophakia following congenital cataract surgery who subsequently underwent 
trabeculectomy with or without MMC (19 consecutive patients, 23 eyes) between January 
1989 and April 2000 at LV Prasad Eye Institute. Patients were identified by searching our 
database for diagnostic codes and by reviewing the old charts. In four patients who 
underwent glaucoma surgery in both eyes, only the first operated eye was included in this 
study. 
All patients underwent a complete ocular examination before and after surgery. The 
information obtained by a retrospective chart review included (1) patient demographics, (2) 
diagnosis of glaucoma, (3) age at cataract surgery, (4) preexisting ocular abnormalities, (5) 
type of cataract, (6) type of procedure or instrumentation, (7) interval between cataract 
surgery and development of glaucoma, (8) pre- and postoperative data including visual 
acuities, disc findings, IOPs, visual field changes and antiglaucoma medications, (9) exposure 
time and dose of MMC, (10) surgical procedure, and (11) significant complications. Informed 
consent was obtained from all patients/parents and Institutional Review Board approval for 
this study was obtained. 
Surgical technique 
All trabeculectomies were performed by one surgeon (AKM) and have been detailed 
previously.13,14 A limbus-based flap of conjunctiva and Tenon's capsule was created. After 
haemostasis of the episcleral blood vessels with wet-field cautery, a one-half thickness 
triangular scleral flap (4 mm base at the limbus) was outlined and dissected anteriorly without 
entry into the anterior chamber. A surgical sponge measuring 4x4 mm2 was soaked in a 
solution of 0.4 mg/ml MMC (mitomycin-C powder was reconstituted in sterile water to give 
the final concentration). The sponge was placed over the dissected bed; a superficial scleral 
flap and the conjunctiva-Tenon layer were then draped over the MMC-soaked sponge so that 
only those ocular tissues in contact with the sponge were directly exposed to MMC. After 3 
min, the sponge was removed and MMC was irrigated thoroughly with 20 ml balanced salt 
solution (BSS). A 2mm x 1mm deep trabecular block was removed, and a peripheral 
iridectomy was performed. 
The scleral flap was closed with three interrupted (one at the apex and one on each side of the 
triangular scleral flap) 10-0 nylon sutures. The conjunctivo-Tenon layer was closed with 8-0 
polyglactin (Vicryl) suture on a tapered needle (Ethicon, Somerville, NJ, USA). After the 
closure, the conjunctiva was shown to be watertight. A drop of antibiotic–corticosteroid 
preparation and cyclopentolate was instilled in the conjunctival sac, and a patch and shield 
were applied on the eye. In cases where MMC was not used, standard trabeculectomy was 
performed with a few modifications in the form of three loose sutures or a single apical suture 
for scleral flap closure, partial Tenonectomy and cautery around the margins of the internal 
osteum. There were no definite criteria for applying or not applying MMC; however, the 
surgeon (AKM) stopped using MMC more recently. 
The postoperative medical regimen initially included 0.1% betamethasone eye drops 
administered every 2 h and then tapered over a period of 6 weeks, depending on the degree of 
inflammation. Cyclopentolate 1% eye drops were given 3 times a day for the first 4 
postoperative weeks. A topical antibiotic (0.3% gentamycin) was also administered 4 times 
daily for 1 week after surgery. 
All patients were seen on the first postoperative day and then at 1, 3, 6 weeks and at every 3 
months thereafter. At each visit, slit-lamp biomicroscopy for chamber depth, corneal 
appearance, IOP, bleb appearance and fundus examination was carried out wherever possible. 
IOP was measured while the patient was awake and in the seated position using a Goldmann 
applanation tonometer whenever patient cooperation permitted. For patients who were unable 
to cooperate with an office exam, a Perkins hand-held applanation tonometer was used during 
examination under anaesthesia using 1% halothane. Age-appropriate methods of visual acuity 
testing were used. 
Surgical success and failure were defined before data analysis. A 'complete' success was 
defined as an IOP at the most recent follow-up visit that was in the range 6–21 mmHg 
without any glaucoma medications, without evidence of glaucoma progression, without 
requirement for further glaucoma surgery, and in the absence of visually devastating 
complications. A 'qualified' success was defined when the previous condition was achieved 
with single topical antiglaucoma medication. Failure was defined if any of the following were 
present: (1) IOP>21 mmHg with two or more medications, (2) additional antiglaucoma 
surgery required, (3) hypotony maculopathy, or (4) any other sight-threatening complications 
like bleb-related infection (BRI) and endophthalmitis. For the purpose of this study, ocular 
hypotony was documented to be present when IOP was <6 mmHGg on two consecutive 
postoperative visits employed to indicate statistical significance. Mann–Whitney U test was 
used to compare the mean IOP between trabeculectomy with MMC and trabeculectomy 
without MMC groups. Kaplan–Meier survival analysis was used to determine the success 
probabilities at various postoperative intervals. Log-rank test was applied to test the equality 
of survival distribution between the two groups. 
Results 
In total, 23 eyes of 19 patients were included in this study. Patient demographics are 
summarized in Table 1. There were 10 males and 9 females in the group. All patients were of 
Asian origin. The mean age at the time of initial cataract surgery was 2.9 3.5 years (range: 
0.2–12 years; median: 1 year). The information regarding the instrumentation or the type of 
surgical procedure for cataract extraction was not available to our patients. The man time 
interval between cataract surgery and diagnosis of glaucoma was 7.2 7.8 years (range: 0–27 
years; median: 5.8 years). The mean age of the patients at the time of trabeculectomy without 
MMC was 11.0 12.4 years (range: 0.3–37 years) and was 8.8 5.5 years (range: 2–18 years) 
in the group with MMC (P=0.649, Mann–Whitney U test). Nine eyes (eight patients) 
underwent trabeculectomy with MMC while 14 eyes (11 patients) underwent trabeculectomy 
without MMC. The mean follow-up was 24.2 17.9 months. 
 
 
 
Table 1 - Patient demographics (23 eyes of 19 patients of glaucoma following congenital 
cataract surgery). 
Demographics  No.  
Age at presentation (years)   
 Mean 9.6 
 Median 6.5 
 Range 0.08–37 
    
Race Asian 
Gender   
 Male 10 
 Female 9 
    
Lens status (no. of eyes)   
 Aphakic 21 
 Pseudophakic 2 
    
Mean interval between cataract surgery and diagnosis of glaucoma (years) 7.2 7.8 
 Median 5.8 
 Range 0–27 
    
Mean age at trabeculectomy (years)   
 Without MMC 11 12.4 
 Range 0.3–37 
 With MMC 8.8 5.5 
 Range 0.2–18 
    
Mean preoperative IOP (mmHg) 34.2 8.9  
 Range 20–52  
Mean postoperative IOP (mmHg) 18.4 12.2  
 Range 2–60  
Mean follow-up (mmHg) 24.2 17.9 
 MMC=mitomycin-C, IOP=intraocular pressure. 
Four patients underwent bilateral trabeculectomy with MMC, but in separate operative 
sessions; only the first eye operated upon was included for statistical analysis in this study. In 
all, 21 eyes were aphakic and two eyes were pseudophakic. The mean horizontal corneal 
diameter was 11.0 1.6 mm. However, the corneal diameter was less than 10 mm in three 
eyes. Two eyes had Peter's anomaly. The mean number of prior surgical procedures was two. 
The mean number of antiglaucoma medications used before trabeculectomy was beta-
blockers in 94.7%, pilocarpine in 36.5%, and tablet acetazolamide in 42.1%. 
The IOP was reduced from a preoperative level of 34.2 8.9 mmHg (range: 20–52) to a 
postoperative level of 18.4+12.2 mmHg (range: 2–60) with a mean follow-up of 24.2 17.9 
months. The mean reduction in IOP in the MMC group was 15.4 17.3 and 16.3 13.8 mmHg 
in the other group (P=0.967, Mann–Whitney U test). 
Complete success was achieved in 36.8% patients with a mean follow-up of 24.2 17.9 
months (range: 1.6–54 months). The IOP was controlled with one antiglaucoma medication 
in 21.1% patients, which was considered as a qualified success. Surgical failure occurred in 
42.1% of patients at a mean postoperative interval of 18.3 16.0 months (range: 0.9–40.2 
months). The success probabilities ( standard error) were 78 1%, 57 13% and 33 13% at 
12, 24 and 36 months, respectively. Figure 1 shows the Kaplan–Meier survival curve of 
overall success rate. Figure 2 shows the Kaplan–Meier survival curve of successful IOP 
control in trabeculectomy with and without MMC. There was no significant difference 
(P=0.5135, log-rank test) in the survival distributions of the two groups. 
Figure 1. Kaplan–Meier survival plot showing overall success rate of modified trabeculectomy 
and trabeculectomy with MMC. 
 
 
Figure 2 - Kaplan–Meier life table estimation of successful intraocular pressure control 
following surgery. The outcome of modified trabeculectomy and trabeculectomy with MMC is 
compared. 
 
 
Preoperative visual acuities are listed in Table 2. The final postoperative visual acuity was the 
same as, or better than, the preoperative level in 76.5% of the eyes that were categorized as a 
success. Four eyes (23.5%), which were categorized as failures, had a decrease in visual 
acuity. Of these, two eyes belonged to a single patient who developed bleb-related 
endophthalmitis. This was successfully treated but the patient subsequently developed 
chronic hypotony and choroidal detachment, which was not amenable to treatment, and the 
final visual acuity dropped from 20/50 to 20/400 in the left eye. 
Table 2 - Preoperative visual acuities in 19 patients. 
Steady fixation and ability to follow light  4 (23.5%)  
<20/400 5 (29.4%) 
>20/100–20/400 5 (29.4%) 
20/50–20/80 2 (11.8%) 
20/20–20/40 1 (5.9%) 
 
The blebs were characterized by their large, elevated, avascular and transparent appearance in 
patients who underwent trabeculectomy with MMC. In contrast, the blebs were diffuse and 
relatively thick-walled in patients who underwent trabeculectomy without MMC as seen in 
Figure 3. 
Figure 3. Diffuse and relatively thick-walled blebs with modified trabeculectomy. 
 
There were no intraoperative complications. The postoperative complications in the two 
groups are listed in Table 3. Two patients developed dellen formation 6 weeks 
postoperatively, which was successfully treated with lubricant drops. Complete healing of the 
dellen occurred after treatment with topical lubricants. Figure 4 documents the anterior 
segment appearance in the right eye of the patient who developed bleb-related 
endophthalmitis. Figure 5 documents the appearance of the same eye after successful 
treatment of endophthalmitis. Similarly, Figures 6 and 7 document the appearance of the 
anterior segment when endophthalmitis developed in the left eye and outcome following 
treatment, respectively. Figures 8 and 9 document the 1 year and 14 months, respectively, of 
the postoperative appearance of the blebs of the right and left eye of the same patient who 
developed bleb-related endophthalmitis. Subsequently, the patient was seen with the 
diagnosis of chronic hypotony with thick choroidals that did not respond to any therapy and 
visual acuity reduced from 20/50 to 20/400 in the left eye. 
Figure 4 - Anterior segment and bleb appearance of the right eye of the patient who developed 
bleb-related endophthalmitis 13 months following trabeculectomy with MMC. 
 
Figure 5 - Appearance of the same eye after successful treatment of endophthalmitis. 
 
Figure 6 - Anterior segment and bleb appearance of the left eye of the same patient who 
developed bleb-related endophthalmitis 1 year and 9 months following trabeculectomy with 
MMC. 
 
Figure 7 - Appearance of the left eye of the patient who developed bleb-related 
endophthalmitis following treatment. 
 
Figure 8 - Appearance of the bleb of the right eye 1 year following treatment of 
endophthalmitis. 
 
Figure 9 - Appearance of the bleb of the left eye 14 months following treatment of 
endophthalmitis. 
 
 
 
Table 3 - Comparison of complications in trabeculectomy with MMC and modified 
trabeculectomy in glaucoma following congenital cataract surgery. 
 
Trabeculectomy with MMC (n=9) Trabeculectomy without MMC (n=14) 
Endophthalmitis 2 eyes (22.2%) — 
Choroidal detachment 3 eyes (33.3%) 2 eyes (14.3%) 
Hypotony maculopathy 3 eyes (33.3%) — 
Encysted bleb 1 eye (11.1%) — 
Shallow AC — 1 eye (7.1%) 
Dellen 2 eyes (22.2%) — 
SPK 3 eyes (33.3%) — 
 MMC=mitomycin-C, AC=anterior chamber, SPK=superficial punctate keratitis. 
Discussion 
Glaucoma in aphakia and pseudophakia is a well-recognized sequelae of congenital cataract 
surgery, but there is still a lack of adequate information regarding its presentation, risk factors 
and management. Glaucoma may occur in either an acute form or chronic form. Acute 
glaucoma is typically of the angle closure type and usually presents in the early postoperative 
period. In contrast, open angle glaucoma (OAG) following congenital cataract surgery is not 
usually diagnosed until many years have passed. In our series, all the patients had open 
angles and the average time interval for the onset of glaucoma following congenital cataract 
surgery was 7.2 7.8 years. This is in accordance with the existing knowledge in the 
literature. Simon et al6 reported a mean time interval of 6.8 years. The average time interval 
between congenital cataract surgery and diagnosis of glaucoma was 12.2 years as reported by 
Asrani and Wilensky;3 while Phelps and Arafat; 23 reported an interval ranging from 2 to 45 
years. Asrani et al24 observed a decreased incidence of open angle glaucoma among eyes 
rendered primarily pseudophakic compared with those that remained aphakic after congenital 
cataract surgery. They reported a single case of open-angle glaucoma found among 377 eyes 
with primary pseudophakia (mean age of patients: 5.1 4.7 years; mean follow-up: 3.9 2.7 
years) following congenital cataract surgery. Extensive literature search has not revealed any 
reported case of OAG after primary IOL implantation of a congenital or developmental 
cataract in the absence of any other anterior segment anomalies.24 Interestingly, our series 
included two such cases and both eyes had pseudophakia with open angle gonioscopically. 
However, multiple surgeons were involved and various techniques of cataract surgery were 
employed, details of which were not known to us. 
Glaucoma following congenital cataract surgery is refractory to surgical intervention for 
several reasons, including young age, history of prior surgery, associated subconjunctival 
scarring, aphakia and pseudophakia itself. Aphakia is also a known risk factor for failure in 
adult trabeculectomy surgery.25,26 Previous reports of outcome of filtering surgery without the 
use of any adjunctive antifibrotic agents in the management of a paediatric glaucoma have 
been disappointing.9,10,11 The use of antifibroproliferative agents such as 5-fluorouracil (5-
FU)27,28 and MMC,29,30 which may improve the surgical prognosis, has been studied 
extensively in adults. Several prospective randomized studies in adults with high-risk 
glaucoma filtering surgery have shown that intraoperative MMC may be a better alternative 
to the use of postoperative 5-FU because MMC-augmented trabeculectomy is shown to have 
resulted in lower overall IOP, decreased dependence on postoperative antiglaucoma 
medication, and decreased corneal toxicity.31,32,33 Khaw et al,34 in an elegant study of cell 
culture analysis, demonstrated the greater effect of MMC as compared to 5-FU on both 
fibroblast proliferation and morphologic characteristics. Encouraging reports of 
intraoperative use of MMC in adults,31,32,33 coupled with the difficulties encountered by 
repeated injections of 5-FU in children, prompted us to use MMC intraoperatively during 
glaucoma filtering surgery in these patients. 
Mitomycin-C has emerged as an effective antimetabolite for topical use during 
trabeculectomy. It is an antineoplastic antibiotic isolated from the fermentation filtrate of 
Streptomyces caespitosus, which has the ability to suppress significantly fibrosis and vascular 
ingrowth after exposure to the filtration site. The time of application of MMC in our study 
was 2–3 min. After a mean follow-up of 24.2 17.9 months, 36.8% of the eyes demonstrated 
successful control of IOP (IOP less than or equal to 21 mmHg). This suggests that glaucoma 
following congenital cataract surgery is refractory to filtering surgery even with the 
intraoperative use of MMC. 
The probability of having IOP<21 mmHg with no antiglaucoma medication and with 
clinically stable glaucoma 1 year after surgery was 0% in the eight aphakic eyes in the study 
by Azuara-Blanco et al.18 The mean age at the time of surgery was 5.7 years in that study, 
while the mean age at surgery was 11.0 12.4 years in trabeculectomy without MMC group 
and 8.5 5.5 in the MMC group in our study. The relatively better success rate in our series 
could be related to the application time of MMC, which was 3 min compared to 2.2 min (0.9 
min lower) in the study by Azaura-Blanco et al. 
Table 4 summarizes the reports evaluating the outcome of glaucoma filtering surgery with 
adjunctive MMC in glaucoma following congenital cataract surgery. With the exception of 
the study reported by Azuara-Blanco et al18 the success rate varied from 50% to 
85%.3,17,18,19,20,21,22 The success rate of the present series is comparable to that reported by 
Walton,22 Asrani and Wilensky,3 Wallace et al21 and Beck et al.17 According to Wallace et 
al21 trabeculectomy with MMC is the most effective treatment in aphakic glaucoma following 
congenital cataract surgery. In sharp contrast, Azuara-Blanco et al18 had a poorer outcome 
and they were forced to comment that an alternative approach to aphakic childhood glaucoma 
may be necessary. Sidoti et al20 also suggested that other therapeutic approaches should be 
explored such as aqueous drainage implants because of the lack of effectiveness of 
trabeculecotmy with MMC in many cases and the potential for complications even when the 
successful control of IOP is achieved. 
Table 4 - Reported series on trabeculectomy with or without mitomycin-C in paediatric aphakic 
glaucoma. 
Author  Year of publication  
No of eyes 
glaucoma  Lens status  Procedure  Success criteria  Success(%) 
Walton22  1995 14 eyes Aphakic Trab.+MMC ? 64 
Asrani and 
Wilensky3  1995 12 eyes Aphakic 
Trab. 5 eyes 
Trab.+MMC 7 
eyes 
IOP<22 mmHg 85 
Wallace et 
al 21  1998 13 eyes Aphakic 
Trab.+MMC 
4 min, 0.2 or 
0.4 mg/ml 
IOP<26 mmHg or 
IOP<21 mmHg 
with medication 
61 
Beck et al 
17  1998 9 eyes Aphakic 
Trab.+MMC 
0.25 or 
0.5 mg/ml for 
5 min 
IOP<22 mmHg 
with or without 
medication 
78 
Azuora-
Blanco et 
al 18  
1999 8 eyes Aphakic 
Trab.+MMC 
0.4 mg/ml; 1–
5 min 
IOP<21 mmHg 
without 
medication 
0 
Freedman 
et al 19  1999 4 eyes Aphakic 
Trab.+MMC 
0.4 mg/ml for 
3–5 min 
IOP 4–16 mmHg 
with medication 50 
Sidoti et al 
20  2000 3 eyes Aphakic 
Trab.+MMC 
0.5 mg/ml for 
1.5–8 min 
IOP 5–21 mmHg 
with medication 66.6 
Mandal et 
al  
2002 
Present 
study 
23 eyes 
Aphakic 21 
eyes 
Pseudophakia 2 
eyes 
Trab.+MMC 
0.4 mg/ml for 
2–3 min 
IOP 6–21 mmHg 
without 
medication with 
medication 
36.8, 
Additional* 
21.1 
* Additional=with medication. 
The role of glaucoma drainage implant surgery as the alternative management of refractory 
glaucoma following congenital cataract surgery deserves mention. The long-term bleb-related 
complications and the potential risk of chemotherapeutic exposure are avoided with the use 
of drainage implants.35 Encouraging reports obtained with the Molteno implants in young 
adults have led several investigators to the application of various other glaucoma drainage 
devices in children and young adults with various refractory glaucomas.36,37,38,39,40,41,42,43 
Molteno et al36 and Billson et al37 reported success rates of 87 and 95%, respectively. 
Recently, Baervelat and Ahmed glaucoma implants have been used to treat refractory 
glaucoma in young adults and paediatric patients, achieving success rates of 86 and 85%, 
respectively.41,42 Molteno et al36 reported success (IOP<20 mmHg without any antiglaucoma 
medication, with a Molteno implant in 19 of 21 eyes with congenital cataracts). Billson et al37 
achieved IOP control (<21 mmHg without medication) in 8 of 11 eyes with childhood 
aphakic glaucoma after a two-stage Molteno implant with a follow-up of 1–7 years. 
Contradictory reports have also been published in the recent literature. Wallace et al21 
implanted nine Molteno implants in patients with aphakia. Although six of the nine 
procedures resulted in IOP control at 6 months, only three maintained IOP control for 12 
months after surgery. Coleman et al43 reported cumulative probability of success as 80 and 
60% at 12 and 24 months, respectively, while Nesher et al39 reported a success rate of 59%. 
In general, the success rates of glaucoma drainage devices in refractory paediatric glaucoma 
are variable and also have a variable rate of complications.36,37,38,39,40,41,42,43 The comparison 
of the results of these studies with the present study is invalid in view of the differences in 
age groups included and racial variations. However, glaucoma drainage implant seems to be 
an interesting alternative in this refractory glaucoma. Only a prospective randomized clinical 
trial comparing the two treatment modalities will identify convincingly the superior surgical 
option for these challenging patients. Drainage implants may be a better alternative to 
trabeculectomy with MMC for aphakic patients who are contact lens dependants, and who 
may be at greater risk for late-onset bleb-related infection and endophthalmitis after 
surgery.44 
Bleb-related infection is a serious complication of trabeculectomy with adjunctive 
chemotherapy and its incidence appears to have increased in recent years.15,17,20,21,45,46,47,48 
Susanna et al15 reported one case in 79 cases (1.26%) and Wallace et al21 noted one case in 
16 eyes (6%). Beck et al17 noted late-onset endophthalmitis in five eyes of five patients (8%) 
at 18–48 months postoperatively; however, four of the five eyes had excellent outcome with 
continued IOP control. In the recent report by Sidoti et al20 five patients (17%) had BRI at a 
mean follow-up of 27.9 months. Of these, two (7%) experienced endophthalmitis with one 
eye becoming phthisical and the other three patients (10%) experienced blebitis. In our own 
series, two eyes of a patient had BRI on separate occasions, which was successfully treated 
but ultimately developed choroidal detachment and hypotony that was refractory to treatment 
and led to severe diminution of vision. The long life expectancy in these patients as well as 
huge thin-walled avascular bleb coupled with difficulty in maintaining proper hygiene in 
children are responsible for the high rate of intraocular infection. Several studies 46,49 have 
reported a higher frequency of endophthalmitis with the use of antimetabolites with 
trabeculectomy in the inferior hemisphere, so it is advisable to avoid such locations. 
Considering the higher incidence of BRI in their series over an extended follow-up interval, 
Sidoti et al20 have suggested caution in using MMC as an adjunct chemotherapy in paediatric 
trabeculectomy. They suggested that when MMC is used as adjunct chemotherapy to 
trabeculectomy in children, a lower dosage (concentration, time of exposure, or both) should 
be considered. Agarwal et al16 reported that 0.2 mg/ml of mitomycin for 4 min is as effective 
as 0.4 mg/ml concentration in high-risk cases of congenital glaucoma, but with a lower 
incidence of complications and thin-walled blebs. 
It is of interest that there were more surgical failures with a higher dosage of MMC in 
uncomplicated congenital glaucoma as reported by Mullaney et al.50 The reason for this is not 
clear. Megevand et al51 found no difference in the final IOP while using MMC with exposure 
time 2 min vs 5 min. Stone et al52 found similar results and the exposure time of MMC (0.3 
mg/ml) ranged from 1 to 5 min. Jampel53 suggested that the largest effect of MMC took place 
during the first minute of drug exposure. Based on the available reports in the literature, it is 
advisable to use lower concentration and shorter exposure time when adjunctive MMC with 
trabeculectomy is planned in paediatric patients. 
A less potent chemotherapeutic agent such as 5-FU may be used in refractory paediatric 
glaucoma. There is a little doubt that MMC carries greater risk than does postoperative 5-FU. 
Zalish et al54 reported good success with postoperative 5-FU in congenital and infantile 
glaucoma. The primary disadvantage of conventional 5-FU treatment is the need for multiple 
postoperative visits to receive the subconjunctival injections. Good outcomes with 
intraoperative sponge 5-FU in adults have been reported by several investigators.55,56,57,58 To 
our knowledge, there is no published report on the results of intraoperative use of sponge 5-
FU in refractory glaucoma following congenital cataract surgery. We think that 
trabeculectomy with intraoperative sponge 5-FU with a short course of postoperative 
subconjunctival supplementation (if required) may be a safer alternative in this type of 
refractory glaucoma. A prospective randomized clinical trial comparing intraoperative MMC 
vs 5-FU in the carefully selected comparable group of patient population seems warranted; 
however, it is probably not feasible, as the patient numbers are small. 
To avoid MMC-related complications, and adjunctive chemotherapy in paediatric glaucoma 
patients, we performed trabeculectomy with tenonectomy in nine patients with application of 
loose 10-0 nylon sutures or a single apical suture for closure of the superficial scleral flap. 
This approach was followed in view of the thin-walled avascular blebs following adjunctive 
antifibrotic therapy, which are prone to infections as documented in the present study as well 
as several other published studies. Although, the success rate of trabeculectomy with or 
without MMC is the same, a large number of cases and longer duration of follow-up is 
required to identify the superior surgical option in this situation. The bleb appearance of the 
patients who did not receive MMC was satisfactory and not prone to blebitis or 
endophthalmitis compared with the patients who received MMC intraoperatively. 
The results of the present study need to be interpreted with caution. The limitations of this 
study include its nonrandomized, retrospective design, the wide variation in the age groups 
included, and arbitrary criteria for use of MMC. In addition, our series is relatively small to 
be able to have the power to detect differences in the outcome of trabeculectomy with or 
without MMC. 
In conclusion, the management of glaucoma following congenital cataract surgery is 
challenging. Young age, subconjunctival scarring, prior surgery and aphakia or pseudophakia 
are significant risk factors for failure. The present study achieved a poor success rate of 
trabeculectomy in a small series of aphakic Asian Indian patients, even with the use of MMC. 
The possibility of bleb-related sequelae and complications should be discussed with the 
patients or parents, and children with filtering blebs who develop red eyes should be 
promptly evaluated. Periodic follow-up is mandatory for life. 
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